CUNY-born digital olfaction technology developer MouSensor will receive funding and expertise from nanoelectronics institute Imec's investment fund.

University of Iowa's medical diagnostics spinout IDx has collected $33m from investors including Optum, bringing the company’s total to $48m.

State-wide innovation hubs under the banner of Michigan Translational Research and Commercialization will receive money from the Michigan Strategic Fund.

The EEG system developer raised the series B funding from investors including UCB and LivaNova and will use it commercialise its lead device.

Alexion will pay $400m upfront for Baxalta-backed Syntimmune, with up to an additional $800m on offer if the autoimmune disease drug developer hits all its milestones.

PharmEasy took its total funding past the $100m mark, six months after collecting some $30m from investors including Manipal Education and Medical Group.

Novo has co-led the series B round together with Omega Funds, adding to a $51.5m series A co-led by GlaxoSmithKline and Pfizer in 2016.

Founded out of Université catholique de Louvain and Wageningen University research, A-Mansia Biotech hopes to commercialise nutritional supplements for patients at heightened cardio-metabolic risk.

Oxford University Innovation expects to form 10 spinouts each year from an initiative for impact-led businesses.

Johnson & Johnson and AstraZeneca will get a chance to exit the orphan disease therapy developer, which has filed for an $86.3m IPO.